AbbVie (ABBV) Stock on November 29, 2025: Skyrizi’s Canada Win, Big-Money Flows and a Hot Valuation Debate
Published: November 29, 2025 AbbVie Inc. (NYSE: ABBV) heads into the final stretch of 2025 trading just below its record highs, after a powerful rally driven by immunology blockbuster drugs Skyrizi and Rinvoq. The stock closed at $227.70 on Friday, November 28, up 0.02% on the day and sitting within a 52‑week range of roughly $164 to $245. StockAnalysis+1 Year to date, AbbVie shares have climbed about 31–32%, and delivered roughly 38% over the past twelve months, easily outpacing the broader market. Simply Wall St+1 Today’s news flow (November 29, 2025) gives investors plenty to chew on: Below is a